FDA greenlights second Ebola treatment in three months, handing new OK to Ridgeback's Ebanga
A husband-and-wife biotech that licensed a Covid-19 antiviral before quickly partnering on it with Merck earlier this summer has a new approval in another highly infectious disease — Ebola.
Ridgeback Biotherapeutics, co-founded by CEO Wendy Holman and her husband Wayne Holman, a hedge fund manager who used to work for a company involved in one of the biggest insider trading scandals in history, has clinched an FDA OK for ansuvimab-zykl to treat the deadly Ebola virus in adults and children. The drug, a monoclonal antibody, will be marketed as Ebanga.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.